Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Serum Cancer Biomarkers Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Hepatocellular Carcinoma Serum Biomarkers
  • 1.3.3 Lung Cancer Serum Biomarkers
  • 1.3.4 Pancreatic & Biliary Tract Cancer Serum Biomarkers
  • 1.3.5 Breast Cancer Serum Biomarkers
  • 1.3.6 Glioblastoma Serum Biomarkers
  • 1.3.7 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global Serum Cancer Biomarkers Market Share by Application (2019-2025)
  • 1.4.2 Hospitals
  • 1.4.3 Academic & Research Institutes
  • 1.4.4 Ambulatory Surgical Centers
  • 1.4.5 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Serum Cancer Biomarkers Market Size
  • 2.1.1 Global Serum Cancer Biomarkers Revenue 2014-2025
  • 2.1.2 Global Serum Cancer Biomarkers Sales 2014-2025
• 2.2 Serum Cancer Biomarkers Growth Rate by Regions
  • 2.2.1 Global Serum Cancer Biomarkers Sales by Regions 2014-2019
  • 2.2.2 Global Serum Cancer Biomarkers Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Serum Cancer Biomarkers Sales by Manufacturers
  • 3.1.1 Serum Cancer Biomarkers Sales by Manufacturers 2014-2019
  • 3.1.2 Serum Cancer Biomarkers Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Serum Cancer Biomarkers Revenue by Manufacturers (2014-2019)
  • 3.2.2 Serum Cancer Biomarkers Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Serum Cancer Biomarkers Market Concentration Ratio (CR5 and HHI)
• 3.3 Serum Cancer Biomarkers Price by Manufacturers
• 3.4 Key Manufacturers Serum Cancer Biomarkers Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Serum Cancer Biomarkers Market
• 3.6 Key Manufacturers Serum Cancer Biomarkers Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Hepatocellular Carcinoma Serum Biomarkers Sales and Revenue (2014-2019)
  • 4.1.2 Lung Cancer Serum Biomarkers Sales and Revenue (2014-2019)
  • 4.1.3 Pancreatic & Biliary Tract Cancer Serum Biomarkers Sales and Revenue (2014-2019)
  • 4.1.4 Breast Cancer Serum Biomarkers Sales and Revenue (2014-2019)
  • 4.1.5 Glioblastoma Serum Biomarkers Sales and Revenue (2014-2019)
  • 4.1.6 Others Sales and Revenue (2014-2019)
• 4.2 Global Serum Cancer Biomarkers Sales Market Share by Type
• 4.3 Global Serum Cancer Biomarkers Revenue Market Share by Type
• 4.4 Serum Cancer Biomarkers Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Serum Cancer Biomarkers Sales by Application

6 United States

• 6.1 United States Serum Cancer Biomarkers Breakdown Data by Company
• 6.2 United States Serum Cancer Biomarkers Breakdown Data by Type
• 6.3 United States Serum Cancer Biomarkers Breakdown Data by Application

7 European Union

• 7.1 European Union Serum Cancer Biomarkers Breakdown Data by Company
• 7.2 European Union Serum Cancer Biomarkers Breakdown Data by Type
• 7.3 European Union Serum Cancer Biomarkers Breakdown Data by Application

8 China

• 8.1 China Serum Cancer Biomarkers Breakdown Data by Company
• 8.2 China Serum Cancer Biomarkers Breakdown Data by Type
• 8.3 China Serum Cancer Biomarkers Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Serum Cancer Biomarkers Breakdown Data by Company
• 9.2 Rest of World Serum Cancer Biomarkers Breakdown Data by Type
• 9.3 Rest of World Serum Cancer Biomarkers Breakdown Data by Application
• 9.4 Rest of World Serum Cancer Biomarkers Breakdown Data by Countries
  • 9.4.1 Rest of World Serum Cancer Biomarkers Sales by Countries
  • 9.4.2 Rest of World Serum Cancer Biomarkers Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Roche
  • 10.1.1 Roche Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Serum Cancer Biomarkers
  • 10.1.4 Serum Cancer Biomarkers Product Introduction
  • 10.1.5 Roche Recent Development
• 10.2 Pfizer
  • 10.2.1 Pfizer Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Serum Cancer Biomarkers
  • 10.2.4 Serum Cancer Biomarkers Product Introduction
  • 10.2.5 Pfizer Recent Development
• 10.3 Novartis
  • 10.3.1 Novartis Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Serum Cancer Biomarkers
  • 10.3.4 Serum Cancer Biomarkers Product Introduction
  • 10.3.5 Novartis Recent Development
• 10.4 Abbott
  • 10.4.1 Abbott Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Serum Cancer Biomarkers
  • 10.4.4 Serum Cancer Biomarkers Product Introduction
  • 10.4.5 Abbott Recent Development
• 10.5 BD
  • 10.5.1 BD Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Serum Cancer Biomarkers
  • 10.5.4 Serum Cancer Biomarkers Product Introduction
  • 10.5.5 BD Recent Development
• 10.6 Merck
  • 10.6.1 Merck Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Serum Cancer Biomarkers
  • 10.6.4 Serum Cancer Biomarkers Product Introduction
  • 10.6.5 Merck Recent Development
• 10.7 Eli Lilly
  • 10.7.1 Eli Lilly Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Serum Cancer Biomarkers
  • 10.7.4 Serum Cancer Biomarkers Product Introduction
  • 10.7.5 Eli Lilly Recent Development
• 10.8 Agilent Technologies
  • 10.8.1 Agilent Technologies Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Serum Cancer Biomarkers
  • 10.8.4 Serum Cancer Biomarkers Product Introduction
  • 10.8.5 Agilent Technologies Recent Development
• 10.9 Boehringer Ingelheim
  • 10.9.1 Boehringer Ingelheim Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Serum Cancer Biomarkers
  • 10.9.4 Serum Cancer Biomarkers Product Introduction
  • 10.9.5 Boehringer Ingelheim Recent Development
• 10.10 AstraZeneca
  • 10.10.1 AstraZeneca Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Serum Cancer Biomarkers
  • 10.10.4 Serum Cancer Biomarkers Product Introduction
  • 10.10.5 AstraZeneca Recent Development
• 10.11 Bristol-Myers Squibb
• 10.12 Novo Nordisk
• 10.13 Allergan
• 10.14 Gilead

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Serum Cancer Biomarkers Sales Channels
  • 11.2.2 Serum Cancer Biomarkers Distributors
• 11.3 Serum Cancer Biomarkers Customers

12 Market Forecast

• 12.1 Global Serum Cancer Biomarkers Sales and Revenue Forecast 2019-2025
• 12.2 Global Serum Cancer Biomarkers Sales Forecast by Type
• 12.3 Global Serum Cancer Biomarkers Sales Forecast by Application
• 12.4 Serum Cancer Biomarkers Forecast by Regions
  • 12.4.1 Global Serum Cancer Biomarkers Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Serum Cancer Biomarkers Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Serum biomarkers are proteins generally detected in urine, blood, and other bodily fluids produced by malignant cells or in reaction to presence/absence of malignant cells. Preferably, biomarkers should have at least one or more than one of the following properties: prompt detection of cancer within high risk population, diagnosis of specific type of cancer, prediction in its growth, screen its treatment response, and detect early recurrence.
The global serum cancer biomarkers market is projected to grow at a rapid pace in the next few years. Key drivers of the market are increase in the number of people suffering from different types of cancer and rise in the geriatric population. Increase in the cancer-afflicted population is anticipated to be another key driver of the market.
In 2019, the market size of Serum Cancer Biomarkers is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Serum Cancer Biomarkers.

This report studies the global market size of Serum Cancer Biomarkers, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Serum Cancer Biomarkers sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Roche
Pfizer
Novartis
Abbott
BD
Merck
Eli Lilly
Agilent Technologies
Boehringer Ingelheim
AstraZeneca
Bristol-Myers Squibb
Novo Nordisk
Allergan
Gilead

Market Segment by Product Type
Hepatocellular Carcinoma Serum Biomarkers
Lung Cancer Serum Biomarkers
Pancreatic & Biliary Tract Cancer Serum Biomarkers
Breast Cancer Serum Biomarkers
Glioblastoma Serum Biomarkers
Others

Market Segment by Application
Hospitals
Academic & Research Institutes
Ambulatory Surgical Centers
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Serum Cancer Biomarkers status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Serum Cancer Biomarkers manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Serum Cancer Biomarkers are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025